United States Prostate Cancer Testing Market is Expected to be Dominated by Pre-Biopsy Testing Biomarker Type Through 2028
Rising incidence of prostate cancer is
expected to drive the growth of the United States Prostate Cancer Testing Market in
the forecast period, 2018-2028
According to
TechSci Research report, “United Prostate Cancer Testing Market - By Region, Competition Forecast
and Opportunities, 2018-2028,” the United States Prostate Cancer Testing Market is
expected to grow with an impressive CAGR during the forecast period 2018-2028. The
rise in prevalence of prostate cancer and need for developing cancer testing
solutions, and acquisitions, expansions, and strategic collaborations among key
players are contributing to the market growth in the United States.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on “United States Prostate Cancer Testing Market”
United States Prostate Cancer Testing Market can be segmented into biomarker type, application, end user, region and competitive landscape.
Based on biomarker
type, the market can be segmented into pre-biopsy/post-negative biopsy testing,
initial evaluation: prostate-specific antigen (Total PSA, Free PSA), post-biopsy
tissue testing. The pre-biopsy testing segment is expected to show an
impressive growth in the forecast period due to the rising rate of cancer
amongst men.
In terms of application,
the market can be split into diagnostics biomarkers, and prognostics biomarkers.
The diagnostics biomarkers segment is expected to show an impressive growth due
to the rising R&D activity for the development of prostate cancer testing in
the forecast period.
Based on the end
user, the market can be classified into cancer research institutes, diagnostic
laboratories, hospitals and clinics, ambulatory surgical center (ASCs), and
others. The hospitals and clinics segment are expected to show an impressive
growth in forecast period due to advanced healthcare facilities and growing
expenditure in research and development in this segment
Major
companies operating in the United States Prostate Cancer Testing Market include:
- F.
Hoffmann-La Roche Ltd (Foundation Medicine, Inc.).
- Siemens
Healthcare GmbH
- OPKO Health,
Inc. (GenPath)
- Myriad
Genetics Inc.
- NeoGenomics
Laboratories
- Danaher.
(Beckman Coulter, Inc.)
- Agilent
Technologies, Inc.
- Abcam plc.
- Bio-Techne.
(ExoDx)
- H.U. Group
Holdings, Inc. (Fujeribio)
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“United States Prostate Cancer Testing
Market is expected to witness significant growth during the forecast period on
account of increasing incidence of prostate cancer. An increase in awareness of
preventive healthcare on account of growing incidence of chronic diseases
further supports the demand for prostate cancer testing market in the United
States. Additionally, increase in emergence of players developing new
procedures of prostate cancer testing and treatment, is expected to create
lucrative opportunities for the market growth in the next few years”
said Mr. Karan Chechi, Research Director with TechSci Research, a research-based
global management consulting firm.
“United States Prostate Cancer Testing
Market By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial
Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue
Testing), By Application (Diagnostics Biomarkers, Prognostics Biomarkers), By
End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and
Clinics, Ambulatory Surgical Center (ASCs), and Others), By Region, Competition
Forecast & Opportunities, 2018-2028F,” has evaluated the future growth potential of United States
prostate cancer testing market and provides statistics & information on
market size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in United States
Prostate Cancer Testing Market.